

INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98) SEP 20 2001 SHEET 1 OF 1				ATTORNEY DOCKET	APPLICATION NO.	
				37522-1002	09/910,461	
				APPLICANT(S) Peter D. Gluckman, et al.		
				INTERNATIONAL FILING DATE	GROUP	
				July 20, 2001	1627	
US PATENT DOCUMENTS						
† EX'R INITIAL	*	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS
						(If appropriate)
FOREIGN PATENT DOCUMENTS						
† EX'R INITIAL	*	REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
<i>MC</i>		B1	0 366 638	10/24/89	EPO	Yes
<i>MC</i>		B2	WO 95/17204	07/29/95	PCT	Yes
<i>MC</i>		B3	WO 98/14202	04/09/98	PCT	Yes
OTHER DOCUMENTS						
† EX'R INITIAL	*	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)			
<i>MC</i>		C1	V. Sara, et al, "Identification of GLY-PRO-GLU (GPE), The Aminoterminal Tripeptide Of Insulin-Like Growth Factor 1 Which Is Truncated In Brain, As A Novel Neuroactive Peptide", Biochemical & Biophysical Research Communications vol. 165, no. 2, 1989, December 15, 1989 pp 766-771.			
<i>MC</i>		C2	L. Nilsson-Hakansson, et al., "Effects of IGF-1, Truncated IGF-1 And The Tripeptide Gly-Pro-Glu On Acetylcholine Release From Parietal Cortex Of Rat Brain", Neuroreport, 4,1111-1114(1993)			
<i>MC</i>		C3	J. Saura, "Neuroprotective Effects Of Gly-Pro-Glu, the N-terminal Tripeptide Of IGF-1, In The Hippocampus In Vitro", Neuroreport Vol. 10, pp. 161-164 (1999).			
<i>MC</i>		C4	V. Sara, "The Biological Role of Truncated Insulin-Like Growth Factor-1 and The Tripeptide GPE In The Central Nervous System", Annals of the New York Academy of Sciences vol. 692, pp 183-191 (1998)			
EXAMINER'S SIGNATURE				DATE CONSIDERED		
<i>B celso A</i>				<i>4/9/03</i>		
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>						
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).						